Mutational profile in HIV-1 GAG cleavage site correlated with phenotypic drug resistance
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 1, 2013
Grant Date -
Oct 11, 2012
app pub date -
Jun 21, 2012
filing date -
May 25, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully